Literature DB >> 2979808

Myasthenia gravis studied by monoclonal antibodies to the acetylcholine receptor.

S J Tzartos1.   

Abstract

Myasthenia Gravis (MG) is caused by auto-antibodies to the nicotinic acetylcholine receptor (AChR). Rapid progress has been made recently in the study of both the disease and the AChR. A significant part of this progress can be attributed to monoclonal antibodies (mAbs) raised against the AChR. These antibodies have been used to identify, purify and study the structure, function and biosynthesis of AChR from electric organs, muscles and neurons. In MG, these mAbs have been used as model auto-antibodies in in vivo and in vitro studies. They have also been used as tools for the structural and functional analysis of the patients' antibodies. A region on a small segment of the AChR alpha-subunit (main immunogenic region) dominates the immunogenicity and probably the pathogenicity of the molecule.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979808

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  5 in total

1.  A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.

Authors:  S Gattenloehner; B Dockhorn-Dworniczak; I Leuschner; A Vincent; H K Müller-Hermelink; A Marx
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

2.  The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors.

Authors:  S Gattenloehner; A Vincent; I Leuschner; S Tzartos; H K Müller-Hermelink; T Kirchner; A Marx
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

3.  Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis.

Authors:  S J Tzartos; E Morel; A Efthimiadis; A F Bustarret; J D'Anglejan; A A Drosos; H A Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

4.  Neonatal myasthenia gravis: antigenic specificities of antibodies in sera from mothers and their infants.

Authors:  S J Tzartos; A Efthimiadis; E Morel; B Eymard; J F Bach
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

5.  Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.

Authors:  Gregory Kordas; George Lagoumintzis; Sotirios Sideris; Konstantinos Poulas; Socrates J Tzartos
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.